A Novel Injectable Chitin-Based Gradient Scaffold System for Long-Term Dermal and Superficial Muscular Rejuvenation: Design of a Phase I/II Clinical Trial (MACRT Protocol) for Apparent Age Reduction

Abstract

This document outlines the design and scientific rationale for a patented, multi-phase clinical intervention termed the Chitin-Boosted Regeneration Protocol (CBRP). CBRP utilizes a gradient-injection strategy of medical-grade β-chitin combined with established bio-stimulatory devices to achieve sustained, cumulative regeneration of dermal and superficial muscular tissue. The proposed Multi-Age Chitin Regeneration Trial (MACRT) is a 5-year, single-blind, randomized, controlled study (N=500) designed to evaluate safety and efficacy across four adult age cohorts (40-70+). The core innovation lies in the sequential administration of a chitin-hyaluronic acid composite, incrementally increasing chitin concentration (20% to 80% v/v) over nine primary treatment sessions. This approach aims to create a biodegradable, bioactive scaffold that guides sustained neocollagenesis, neoelastogenesis, and tissue remodeling, moving beyond transient volumetric filling to true structural rejuvenation.

  1. Introduction & Rationale

Current aesthetic medicine relies heavily on hyaluronic acid (HA) fillers and collagen-stimulating energy devices. While effective, these offer temporary correction or incremental improvement. True tissue regeneration requires a supportive extracellular matrix (ECM) scaffold that directs cellular activity over extended periods. Chitin, a biocompatible and biodegradable polysaccharide, is an FDA-cleared material for wound dressings and is established in tissue engineering as a scaffold that promotes fibroblast adhesion, proliferation, and collagen deposition.

The CBRP hypothesizes that a strategically injected, slow-degrading chitin scaffold, delivered in a concentration gradient and synergized with controlled micro-injury (via microneedling, radiofrequency, HIFU), will provide a sustained regenerative stimulus. This “bio-lifting” effect targets the underlying structural decline of aging skin and superficial musculature, aiming for durable (>3 year) improvements in skin thickness, elasticity, and muscle tone.

  1. Investigational Product & Mechanism of Action

2.1 CBRP Formulation: The product is an injectable sterile composite. Its composition evolves across three treatment phases:

· Phase 1 (Priming; Injections 1-3): 20% β-chitin nanofibers, 80% cross-linked HA. Functions as a hydrating base layer and introduces chitin to the tissue microenvironment.

· Phase 2 (Building; Injections 4-6): 50% β-chitin, 30% HA, 20% Calcium Hydroxylapatite (CaHA). Provides enhanced scaffold density and additional collagen-stimulatory signal via CaHA.

· Phase 3 (Consolidation; Injections 7-9): 80% β-chitin nanofibers, suspended in a growth factor-enriched carrier. Delivers a high-density, porous matrix for deep tissue integration and remodeling.

2.2 Mechanism: Injected chitin forms a temporary, interconnecting 3D network. It acts as a chemoattractant for fibroblasts and a template for organized ECM deposition (Collagen Types I, III, elastin). Concurrent energy-based devices (RF, HIFU) provide thermal and mechanical stress, upregulating TGF-β and PDGF pathways, thereby “activating” the scaffold. The slow enzymatic degradation of chitin (weeks to months) ensures a continuous regenerative stimulus, leading to cumulative tissue gain.

  1. Clinical Trial Design (MACRT Protocol)

3.1 Study Design: Phase I/II, single-blind, randomized, standard-care controlled, multi-center trial.

3.2 Participants: 500 subjects stratified into 5 groups (n=100 each):

· Group A: Age 70+, targeting laxity and atrophy.

· Group B: Age 60-69.

· Group C: Age 50-59.

· Group D: Age 40-49 (prevention focus).

· Group E (Control): Age-matched, receiving a standard 9-session HA filler protocol.

3.3 Intervention: All treatment groups receive the 9-injection CBRP protocol over 28 weeks, paired with specified energy devices (Microneedling, RF, HIFU). Followed by bi-annual maintenance boosters.

3.4 Primary Endpoints (24 Months):

· Structural: ≥30% increase in mid-dermal thickness measured by high-frequency ultrasound.

· Functional: ≥15% increase in grip strength (Group A/B) or muscle cross-sectional area (MRI) in treated facial regions.

· Aesthetic: Significant improvement in validated grading scales (e.g., Global Aesthetic Improvement Scale, Visual Youth Index).

3.5 Safety Monitoring: Comprehensive schedule including weekly checks initially, then monthly/quarterly. Biomarkers (CRP, IL-6), high-resolution imaging (Ultrasound, MRI), and documentation of all adverse events.

  1. Expected Results & Patentable Claims

Based on pre-clinical data and the mechanism, the protocol is projected to yield:

· Dermal regeneration: 30-50% increase in thickness, 25-30% improvement in elasticity.

· Apparent age reduction of 10-20 years as assessed by blinded evaluators.

· Results that improve through Years 2-3 post-treatment before stabilizing, indicating ongoing remodeling.

Key Novel and Patentable Aspects:

  1. The Gradient Injection Protocol: The specific sequence and escalating concentration of chitin (20% → 50% → 80%) to achieve phased tissue integration and regeneration.

  2. The Combination Regimen: The unique, defined pairing of specific chitin-HA-CaHA composite formulations with specific energy devices at defined timepoints to create a synergistic “scaffold + stimulation” effect.

  3. Application for Superficial Muscular Rejuvenation: The use of a deep-dermal/subcutaneous chitin scaffold in conjunction with HIFU to potentially improve muscular tone and volume, a novel indication.

  4. The Integrated System: The CBRP as a complete, multi-session treatment system kit comprising the specific formulations, a defined injection protocol, and a specified schedule of adjunctive procedures.

  5. Conclusion

The CBRP and its associated MACRT trial design represent a translational application of tissue engineering principles into aesthetic and regenerative medicine. By utilizing an approved biomaterial (chitin) in a novel, sequential formulation with synergistic procedures, this protocol aims to shift the paradigm from temporary correction to long-term, structural rejuvenation. The documented design provides a framework for clinical validation and forms the basis for robust intellectual property protection covering the method, composition, and application system.

References

  1. K. S. V. Kumar, et al. “Chitin Scaffolds in Tissue Engineering.” Int J Mol Sci. (2011).

  2. [Author]. “Enhanced Biological Regeneration Simulator (EBRS) Concept.” L-Model Blog. (2025).

  3. M. Rinaudo. “Chitin and chitosan: Properties and applications.” Prog Polym Sci. (2006).

  4. Relevant FDA 510(k) clearances for chitin-based wound care products.

  5. Clinical guidelines for the use of HA fillers, CaHA, RF, and HIFU devices.

6.แนวคิดการทดลองทางคลินิก Chitin-Boosted Regeneration

7.Enhanced Biological Regeneration Simulator (EBRS)

8.Integrated Bio-Stimulation for System Reset and Tissue Regeneration (I-BSRT)

CBRP Treatment Schedule Detail (Per Subject)

WEEKS: 0 2 4 8 12 16 20 24 28 … 6-Month Intervals …

INJ#: 1 2 3 4 5 6 7 8 9 (Boosters)

FORMULA: 20% 20% 20% 50% 50% 50% 80% 80% 80% 50%

Chn Chn Chn Chn Chn Chn Chn Chn Chn Chn

                  • +

80% 80% 80% 30% 30% 30% GF GF GF HA

HA HA HA HA HA HA Cr Cr Cr

        • +

20% 20% 20% 20% 20%

Ca Ca Ca Ca Ca

HA HA HA HA HA

DEVICE: MN MN MN RF RF RF HIFU HIFU HIFU LLLT

(Priming) (Building) (Consolidation) (Maintenance)

Study Arm & Endpoint Overview

GROUP n AGE FOCUS PRIMARY ENDPOINTS (24 Months)

A (Active) 100 70+ Skin Laxity, Atrophy • Dermal Thickness (US) ↑30%

• Grip Strength ↑15%

• Visual Youth Index (VYI) ↓20 pts

B (Active) 100 60-69 Prevention, Optimization• Elastin Content (Biopsy) ↑

• Muscle CSA (MRI) ↑12-18%

• Wrinkle Depth ↓

C (Active) 100 50-59 Prevention, Optimization• Same as Group B + Collagen Density

D (Active) 100 40-49 Maintenance, Enhancement• Skin Quality Metrics (Hydration, Elasticity)

• Prevention of Age-Related Decline

E (Control) 100 Age-Matched Standard Care • Same metrics as matched active group

• Receives Standard HA Filler Protocol